GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-yearStrong cumulative ...

The state auditor report found poor record keeping and a lack of therapy to accompany psychotropic medications.

People are hungry for information about their bodies. Nearly one-third of Americans don smartwatches and other wearable ...

As the fiscal year 2025 begins, the Annual Enrollment Period (AEP) for Medicare opens, offering a crucial window for ...

Applied Therapeutics, Inc. (Nasdaq: APLT) (the“Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications ...

Ensysce Biosciences is a clinical-stage pharmaceutical company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP ...

Niva Bupa faces intense competition from established players and new entrants, which could erode its market position. Lagging ...

Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –– Total ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsEli Newbrun-Mintz - Senior Investor ...

CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...